TrialAmerican journal of hematology2021

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.

Jesus G Berdeja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.